GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer. The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
"Researchers at the UC San Diego School of Medicine are focused on creating improved therapies for brain cancer patients. As such, we were one of the first to show robust expression of PSMA in the vasculature of glioblastomas, as well as in other gliomas, which formed the rationale to proceed with G-202 in a GBM clinical trial," said Santosh Kesari, MD, PhD, co-investigator, neuro-oncologist and director of the Translational Neuro-Oncology Laboratories at UC San Diego Moores Cancer Center.
"We are excited to open this clinical trial using a novel tumor-targeting technology in recurrent glioblastoma patients with the goal of improving survival and identifying biomarkers of response," said principal investigator, David Piccioni, MD, PhD.
"The GBM trial constitutes another milestone in our plan to develop G-202 in multiple cancer indications," said Craig Dionne, PhD, GenSpera CEO. "We are particularly pleased to collaborate with Dr. Kesari and his colleagues, who have been so instrumental in developing the rationale for potential utility of G-202 in GBM and other brain tumors."
12-week coffee compound study shows promising results for weight and fat reduction in at-risk individuals